These medications will no longer be reimbursed. As of November 1st, a new list will be in place that will worry patients.
- Bad news for some patients, including those with cancer and rare diseases.
- From November 1 this year, some drugs used to treat these diseases will no longer be reimbursed.
- These drugs will be excluded from public funding under the Emergency Access to Drug Technology (EDT) program. A full list is available for download below.
The Ministry of Health has just announced a "list of medicinal products not eligible for funding under the Emergency Access to Drug Technologies (RDTL ) procedure." Drugs on this list will lose reimbursement at the end of October this year.
At the same time, the Ministry of Health informed that "patients who started treatment with a medicinal product not subject to financing under the emergency access to drug technologies procedure before the date of validity of the relevant list have the right to continue treatment provided that the effectiveness of the previous treatment is proven ."
Information about continuing treatment should be forwarded by the healthcare provider to the appropriate local branch of the National Health Fund.
- the ministry notes.
A procedure that allows financing the treatment of extremely seriously ill patientsEmergency Access to Drug Technologies (RDTL) is a procedure that allows the National Health Fund to finance the treatment of exceptionally seriously ill patients when a given therapy is not yet reimbursed but can save health or life.
An application for financing a drug is submitted by a hospital or doctor, and each decision is individually analyzed by the Ministry of Health.
As Dziennik Gazeta Prawna reminds, RDTL is used by, among others, patients:
- with cancer for which there are no other therapeutic options;
- with rare diseases, e.g. SMA, hemophilia, hereditary angioedema;
- with severe autoimmune diseases when standard treatment has failed.
According to the announcement and list published by the Ministry of Health, at the end of October 2025, the following drugs will no longer be reimbursed under the RDTL procedure (according to a study by the Rynek Zdrowia portal):
- Adynovi (Rurioctocogum alfa pegolum) - prevention of bleeding in children with hemophilia A and B;
- Afinitor (Everolimus) - treatment of patients with advanced breast cancer using everolimus;
- Aimovig (Erenumab) - chronic migraine;
- Berinert 2000 (C1-esterase inhibitor) - hereditary angioedema (HAE);
- Ebglyss (Lebrikizumab) - atopic dermatitis;
- Enbrel (Etanerceptum) - treatment of active rheumatoid arthritis and juvenile idiopathic arthritis;
- Fotivda (Tivozanib hydrochloride monohydrate) - treatment of kidney cancer;
- Ilaris (Canakinumab) - treatment of congenital autoinflammatory syndromes;
- Imjudo (Tremelimumabum) - hepatocellular carcinoma;
- Kyprolis (Carfilzomibum) - multiple myeloma;
- Lojuxta (Lomitapidum) - familial hypercholesterolemia;
- Mekinist (Trametinib) - non-small cell lung cancer;
- Myalepta (Metreleptinum) - lipodystrophy;
- Ocaliva (Acidum obeticholicum) - primary biliary cholangitis;
- Ozurdex (Dexamethasonum) - retinal vein occlusion;
- Raxone (Idebenone) - treatment of Leber's hereditary optic neuropathy (LHON);
- Sialanar (Glycopyronium bromidum) - cerebral palsy;
- Signifor (Pasireotidum) - Cushing's disease;
- Tecentriq (Atezolizumab) - breast cancer;
- Tysabri (Natalizumab) - multiple sclerosis;
- Vyndaqel (Tafamidisum) - cardiomyopathy in the course of transthyretin amyloidosis;
- Zolgensma (Onasemnogene abeparvovecum) - spinal muscular atrophy (SMA).
The full list of 85 drugs that are no longer reimbursed is available for download below.
